By Billy Candra 
A groundbreaking study led by Professor Sophia Karagiannis at King’s College London has unveiled the precise mechanism by which a novel IgE antibody therapy, MOv18, re-engages the body’s own immune system to combat ovarian cancer. This pivotal research, published in Nature Communications, offers a significant stride in understanding patient responses to this emerging therapy and holds immense promise for individuals battling a disease notoriously resistant to conventional treatments. The findings not only elucidate the unique action of IgE antibodies but also pave the way for more effective, targeted immunotherapies.
The Unmet Need: Ovarian Cancer and Immunotherapy’s Limitations
Ovarian cancer remains one of the most challenging gynecological malignancies to treat, largely due to its often late diagnosis, aggressive nature, and high rates of recurrence and drug resistance. According to Cancer Research UK, around 7,500 women are diagnosed with ovarian cancer each year in the UK, with survival rates significantly lower than many other cancers, particularly when diagnosed at advanced stages. The standard treatment regimen typically involves surgery followed by chemotherapy, but many patients experience relapse, underscoring the urgent need for innovative therapeutic strategies.
Immunotherapy, a revolutionary approach that harnesses the body’s immune system to fight cancer, has transformed the landscape for several cancer types. However, its success in ovarian cancer has been limited. The vast majority of antibody treatments currently employed in cancer therapy are based on immunoglobulin G (IgG) antibodies. While IgG antibodies have shown remarkable efficacy in certain solid tumours and haematological malignancies, they have largely proven ineffective against ovarian cancer. This limited success is partly attributed to the highly immunosuppressive tumour microenvironment characteristic of ovarian cancer, which actively disarms immune cells that would otherwise target malignant cells. Existing IgG antibodies, which primarily activate immune cells circulating in the bloodstream, often struggle to penetrate and overcome this hostile environment within solid tumours.
Pioneering a New Frontier: The IgE Antibody Approach
King’s College London researchers have been at the forefront of a paradigm shift, being the first globally to develop a cancer treatment derived from a fundamentally different class of antibody: immunoglobulin E (IgE). Unlike its more common cousin, IgG, IgE is best known for its crucial role in triggering allergic reactions and stimulating immune responses against parasitic infections. What makes IgE particularly compelling for cancer therapy, however, is its distinct binding affinity. IgE antibodies bind with exceptionally high avidity to immune cells found directly within tissues, as opposed to the more transient interactions of IgG with circulating immune cells. This unique characteristic led Professor Karagiannis’s team to explore the potential of harnessing IgE’s potent immune-boosting capabilities specifically against solid cancers, where immune cells within the tumour microenvironment are often suppressed.
The team focused their investigations on a specific IgE antibody, MOv18, meticulously exploring its capacity to activate immune cells isolated from ovarian cancer patients and to influence the complex immune landscape within the tumour environment. Their research revealed that MOv18 IgE operates through a novel mechanism, effectively reversing the immune system’s suppression imposed by the tumour. It achieves this by activating diverse populations of immune cells to mount a coordinated attack against the cancer.
From Bench to Bedside: Promising Clinical Trial Results
The journey of MOv18 IgE from a conceptual breakthrough to a tangible therapeutic candidate has already seen significant progress. The treatment has demonstrated promising early results in a phase Ia clinical trial, a critical initial step designed to assess safety, dosage, and preliminary efficacy in humans. This trial was meticulously designed and executed by the King’s researchers themselves, in collaboration with the National Institute for Health and Care Research (NIHR) Guy’s and St Thomas’ Clinical Research Facility and with the crucial support of Cancer Research UK’s Centre for Drug Development.
Remarkably, even at low doses, MOv18 IgE led to the shrinkage of a tumour in a patient with ovarian cancer who had previously exhausted conventional therapeutic options and had shown no response to other treatments. This early clinical success underscored the urgent need to understand the precise biological mechanisms driving this unprecedented response. The new study published in Nature Communications was specifically undertaken to unravel how MOv18 IgE functions within the unique and challenging immune environment of ovarian cancer.
Unravelling the Biology: Macrophages, T-cells, and the Tumour Microenvironment
The multidisciplinary study brought together experts from King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, the Medical University of Vienna, Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, and SeromYx Systems, Inc. Their collaborative efforts focused on deciphering how MOv18 IgE interacts with various immune cell subsets in ovarian cancer patients, with a particular emphasis on macrophages.
Macrophages are fundamental immune cells typically tasked with fighting infections and eliminating microorganisms. However, cancer possesses a sinister ability to corrupt these vital defenders. Within the tumour microenvironment, cancer cells can reprogram macrophages, suppressing their inherent ability to trigger an immune response and instead co-opting them to support tumour growth and metastasis. This subversion creates an immunosuppressive barrier that shields the cancer from immune attack.
Previous research conducted in animal models had hinted that MOv18 IgE could effectively reactivate these corrupted macrophages, redirecting their function towards actively fighting the cancer. To validate these observations in a human context, the research team embarked on a rigorous investigation. They first collected macrophages from healthy donors and then exposed them to cancerous fluid samples obtained from the peritoneal cavity—the primary site of ovarian cancer spread—of patients with ovarian cancer. In parallel, they directly isolated macrophages from these patient-derived cancerous fluid samples, all of which were collected from Guy’s and St Thomas’ NHS Foundation Trust.
In both experimental setups, the researchers consistently observed that ovarian cancer profoundly suppressed the immune activity of macrophages. Crucially, however, they discovered that MOv18 IgE possessed the unique ability to bind to and activate these suppressed macrophages, empowering them to effectively kill ovarian cancer cells. Furthermore, this activation by MOv18 IgE achieved another critical feat: it reversed the immunosuppressive effect that ovarian cancer macrophages exerted on other key immune cells known as T cells. T cells are indispensable for maintaining long-term anti-cancer immune responses in patients, and their re-engagement is vital for durable therapeutic effects.
Dr. Gabriel Osborn, who conducted this pivotal research during his PhD at King’s College London, articulated the significance of these findings: "We found that in patients, ovarian cancer reprogrammed macrophages away from normal immune activation. Instead, they formed an immunosuppressive web in association with T cells, that could restrict anti-cancer immunity in patients. MOv18 IgE however induced patient macrophages to kill cancer cells and undergo a highly inflammatory activation, which reversed their suppressive effects on T cells. This study adds important patient-level information to support what we previously observed for MOv18 IgE in the laboratory and reveals, for the first time, that IgE-driven macrophage stimulation can activate the wider tumour immune system." This statement highlights the novel understanding of how IgE can orchestrate a broader immune response, not just activating individual cells but also breaking down the complex immunosuppressive networks within the tumour.
Clinical Validation: Biopsy Analysis Confirms Mechanism
To bridge the gap between laboratory findings and real-world patient responses, the team extended their investigation to analyse tumour biopsies from two patients who had participated in the phase Ia clinical trial. They meticulously examined a biopsy taken from each patient before treatment with MOv18 IgE and compared it with a second biopsy collected after treatment. The analysis revealed a significant increase in the numbers of both macrophages and T cells within the post-treatment samples. This in vivo observation provided compelling clinical evidence, strongly indicating that these two groups of immune cells are indeed key players in the anti-tumour activity mediated by MOv18 IgE. This direct clinical evidence further solidifies the mechanistic insights gained from the in vitro and ex vivo studies.
Expert Perspectives and Future Directions
Professor Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy at King’s College London and senior author of the study, emphasized the foundational importance of this research: "Understanding the biology of how a treatment works is essential for bringing treatments closer to patients. We found that immune cells which are otherwise inhibited in the ‘microenvironment’ of the tumour, are directed by IgE to target the cancer cells. While we are still progressing with clinical testing in patients, it is imperative that we continue in our quest towards understanding how MOv18 IgE, and a wider panel of IgE-based antibodies we are studying, harness the immune system in different groups of patients and cancer types." Her statement underscores the commitment to both clinical translation and deeper scientific exploration to maximize the potential of IgE therapies.
Dr. Debra Josephs, consultant medical oncologist at Guy’s and St Thomas’ NHS Foundation Trust and a co-author of the study, played a crucial role in guiding MOv18 IgE through preclinical research towards clinical testing. She highlighted the broader objective: "Our focus is to deepen our understanding of the immune system and its interaction with cancer, with the goal of discovering better treatments for patients. During the preclinical development of MOv18 IgE we demonstrated the important role of activation and migration of tumour-associated macrophages into cancer lesions for this antibody treatment to be effective. This research marks an important next step in the development of MOv18 IgE by advancing our understanding of macrophage-mediated mechanisms, thus supporting the therapeutic potential of this novel antibody." Her perspective, rooted in direct patient care and clinical translation, reinforces the practical impact of these scientific discoveries.
Professor James Spicer, Professor of Experimental Cancer Medicine at King’s College London, consultant in medical oncology at Guy’s and St Thomas’ NHS Foundation Trust, and Chief Clinical Investigator of the MOv18 IgE Phase Ia trial, also a co-author, articulated the overarching clinical imperative: "We need to achieve better outcomes for our patients. Clear progress is being made by studying the immune system and the environment in which the cancer grows. In our ongoing research we are striving to understand how we can capitalise on the power of IgE to develop novel effective treatments, which will complement established IgG antibody drugs used in the clinic." Professor Spicer’s comments highlight the collaborative and ongoing nature of the research, aiming to integrate IgE therapies into the existing arsenal of cancer treatments.
Broader Impact and Implications
The publication of this research in Nature Communications signifies its high scientific merit and potential impact. The work was generously supported by key funding bodies including Cancer Research UK, the Medical Research Council, and Breast Cancer Now, whose investments enable such pioneering research that ultimately benefits patients.
This study marks a significant milestone in the development of IgE-based immunotherapies. By demonstrating that IgE antibodies can effectively reprogram the immunosuppressive tumour microenvironment in ovarian cancer patients, the research opens new avenues for treating cancers that have historically been resistant to conventional immunotherapy. The ability of MOv18 IgE to activate macrophages and subsequently re-engage T cells suggests a robust and multifaceted immune response, which is often crucial for achieving durable remissions in cancer.
The implications extend beyond ovarian cancer. The principles uncovered here – of IgE’s unique ability to bind to tissue-resident immune cells and reverse tumour-induced immunosuppression – could potentially be applied to a wider range of solid tumours where the tumour microenvironment similarly thwarts immune responses. This research not only provides a deeper understanding of the specific MOv18 IgE antibody but also validates the entire concept of IgE-based immunotherapies as a powerful new class of anti-cancer agents. As clinical trials progress and the understanding of IgE’s mechanisms continues to evolve, this novel approach offers a beacon of hope for patients with challenging cancers, promising a future where the body’s own immune system can be more effectively marshalled to conquer disease. The collaborative spirit demonstrated by the international team, coupled with strong foundational funding, exemplifies the concerted effort required to translate cutting-edge science into life-saving treatments.
